[
  {
    "ts": "2025-09-30T21:01:37+00:00",
    "headline": "Defensive stocks show deep value as cyclicals run hot, UBS says",
    "summary": "Investing.com-- Defensive plays like healthcare equipment and benchmark pharma now offer deeper value at a time when cyclical sectors are trading at historically expensive levels and are pricing in a sharp earnings reboundd despite cooling domestic demand in the US and stuttering Eurozone growth.",
    "url": "https://finance.yahoo.com/news/defensive-stocks-show-deep-value-210137007.html",
    "source": "Investing.com",
    "provider": "yfinance",
    "raw": {
      "id": "279c4e57-2678-3b6f-bbae-6853e738e74a",
      "content": {
        "id": "279c4e57-2678-3b6f-bbae-6853e738e74a",
        "contentType": "STORY",
        "title": "Defensive stocks show deep value as cyclicals run hot, UBS says",
        "description": "",
        "summary": "Investing.com-- Defensive plays like healthcare equipment and benchmark pharma now offer deeper value at a time when cyclical sectors are trading at historically expensive levels and are pricing in a sharp earnings reboundd despite cooling domestic demand in the US and stuttering Eurozone growth.",
        "pubDate": "2025-09-30T21:01:37Z",
        "displayTime": "2025-09-30T21:01:37Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Investing.com",
          "url": "https://www.investing.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/defensive-stocks-show-deep-value-210137007.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/defensive-stocks-show-deep-value-210137007.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ALC.SW"
            },
            {
              "symbol": "BSX"
            },
            {
              "symbol": "ABT"
            },
            {
              "symbol": "FRE.DE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-30T20:57:51+00:00",
    "headline": "Piper Sandler Reaffirms its Overweight Rating and $115 Price Target on Boston Scientific Corporation (BSX)",
    "summary": "Boston Scientific Corporation (NYSE:BSX) is one of the 14 Stocks That Will Double in the Next 5 Years. On September 25, 2025, Piper Sandler reaffirmed its Overweight rating and $115 price target on Boston Scientific Corporation (NYSE:BSX), a $145.3 billion medical products company, citing confidence in the CHAMPION-AF study as a major growth driver for its Watchman […]",
    "url": "https://finance.yahoo.com/news/piper-sandler-reaffirms-overweight-rating-205751650.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "fe75df3c-1a52-3467-889b-8826c33b9201",
      "content": {
        "id": "fe75df3c-1a52-3467-889b-8826c33b9201",
        "contentType": "STORY",
        "title": "Piper Sandler Reaffirms its Overweight Rating and $115 Price Target on Boston Scientific Corporation (BSX)",
        "description": "",
        "summary": "Boston Scientific Corporation (NYSE:BSX) is one of the 14 Stocks That Will Double in the Next 5 Years. On September 25, 2025, Piper Sandler reaffirmed its Overweight rating and $115 price target on Boston Scientific Corporation (NYSE:BSX), a $145.3 billion medical products company, citing confidence in the CHAMPION-AF study as a major growth driver for its Watchman […]",
        "pubDate": "2025-09-30T20:57:51Z",
        "displayTime": "2025-09-30T20:57:51Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/8e984c21a437e828274169c9f37cff34",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Piper Sandler Reaffirms its Overweight Rating and $115 Price Target on Boston Scientific Corporation (BSX)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/N1kGFhgTLsQND_v8aNFidQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/8e984c21a437e828274169c9f37cff34.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PaZn2_8WrEfl9FlzTJJbsA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/8e984c21a437e828274169c9f37cff34.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/piper-sandler-reaffirms-overweight-rating-205751650.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/piper-sandler-reaffirms-overweight-rating-205751650.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BSX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]